Logo
x

Search

Subscribe Now

osimertinib

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

  • March 11, 2021
AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage EGFR-Mutated Lung Cancer

AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage...

  • September 21, 2020
AstraZeneca Reports P-III Trial (FLAURA2) Results of Tagrisso (osimertinib) for the Treatment of EGFR-Mutated Advanced Lung Cancer

    AstraZeneca Reports P-III Trial (FLAURA2) Results of Tagrisso (osimertinib) for the Treatment of EGFR-Mutated Advanced Lung Cancer

    • May 17, 2023
    AstraZeneca Reports P-III Trial (ADAURA) Results of Tagrisso (osimertinib) for Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer

      AstraZeneca Reports P-III Trial (ADAURA) Results of Tagrisso (osimertinib) for Adjuvant Treatment of Early-Stage EGFR-Mutated Lung...

      • March 10, 2023
      Thermo Fisher and AstraZeneca Enters into Multiyear Agreement to Develop Companion Diagnostic Test

        Thermo Fisher and AstraZeneca Enters into Multiyear Agreement to Develop Companion Diagnostic Test

        • January 25, 2023
        HUTCHMED Presents P-II (SAVANNAH) Trial Results of Savolitinib + Tagrisso (osimertinib) for EGFR-Mutated NSCLC at WCLC 2022

          HUTCHMED Presents P-II (SAVANNAH) Trial Results of Savolitinib + Tagrisso (osimertinib) for EGFR-Mutated NSCLC at WCLC 2022

          • July 13, 2022
          Insights+: Breakthrough Therapy Designation by the US FDA in 2020

            Insights+: Breakthrough Therapy Designation by the US FDA in 2020

            • March 11, 2021
            AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage EGFR-Mutated Lung Cancer

              AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage...

              • September 21, 2020
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.